$DMAC
DiaMedica Therapeutics Inc.

2021 Q4 Form 10-Q Financial Statement

#000143774921026175 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.375M $1.084M $1.140M
YoY Change 19.57% -4.91% 9.62%
% of Gross Profit
Research & Development $1.871M $2.332M $2.158M
YoY Change -40.03% 8.06% 33.46%
% of Gross Profit
Depreciation & Amortization $6.000K $6.000K $10.00K
YoY Change -40.0% 0.0%
% of Gross Profit
Operating Expenses $3.246M $2.332M $2.158M
YoY Change -23.98% 8.06% 33.46%
Operating Profit -$3.416M -$3.319M
YoY Change 2.92% 24.73%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $7.000K -$27.00K $128.0K
YoY Change -91.25% -121.09% -43.11%
Pretax Income -$3.239M -$3.443M -$3.191M
YoY Change -22.7% 7.9% 30.99%
Income Tax $7.000K $7.000K $2.000K
% Of Pretax Income
Net Earnings -$3.246M -$3.450M -$3.193M
YoY Change -22.71% 8.05% 30.43%
Net Earnings / Revenue
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$122.5K -$181.2K -$191.1K
COMMON SHARES
Basic Shares Outstanding 26.44M 18.79M 18.74M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.81M $48.12M $30.60M
YoY Change 42.68% 57.27% 214.11%
Cash & Equivalents $4.707M $16.22M $9.797M
Short-Term Investments $45.10M $31.90M $20.80M
Other Short-Term Assets $197.0K $336.0K $150.0K
YoY Change 181.43% 124.0% -62.5%
Inventory
Prepaid Expenses $84.00K
Receivables $130.0K $104.0K $335.0K
Other Receivables $0.00
Total Short-Term Assets $45.44M $48.54M $31.11M
YoY Change 62.74% 56.04% 187.86%
LONG-TERM ASSETS
Property, Plant & Equipment $70.00K $70.00K $50.00K
YoY Change -5.41% 40.0% -26.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $112.0K $127.0K $164.0K
YoY Change -35.63% -22.56% -29.61%
TOTAL ASSETS
Total Short-Term Assets $45.44M $48.54M $31.11M
Total Long-Term Assets $112.0K $127.0K $164.0K
Total Assets $45.55M $48.66M $31.27M
YoY Change 62.13% 55.63% 183.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $509.0K $699.0K $720.0K
YoY Change -53.69% -2.92% 130.77%
Accrued Expenses $966.0K $861.0K $658.0K
YoY Change 11.81% 30.85% -21.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.000K $4.000K $10.00K
YoY Change -60.0% -60.0% 0.0%
Total Short-Term Liabilities $1.524M $1.624M $1.443M
YoY Change -24.85% 12.54% 19.75%
LONG-TERM LIABILITIES
Long-Term Debt $3.000K $4.000K $10.00K
YoY Change -70.0% -60.0% 0.0%
Other Long-Term Liabilities $0.00 $0.00 $60.00K
YoY Change -100.0% -100.0% -50.0%
Total Long-Term Liabilities $3.000K $4.000K $69.00K
YoY Change -94.34% -94.2% -48.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.524M $1.624M $1.443M
Total Long-Term Liabilities $3.000K $4.000K $69.00K
Total Liabilities $1.527M $1.628M $1.512M
YoY Change -26.62% 7.67% 12.92%
SHAREHOLDERS EQUITY
Retained Earnings -$82.50M -$79.30M -$64.71M
YoY Change 19.72% 22.55% 19.53%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $44.02M $47.00M $29.76M
YoY Change
Total Liabilities & Shareholders Equity $45.55M $48.66M $31.27M
YoY Change 62.13% 55.63% 183.27%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$3.246M -$3.450M -$3.193M
YoY Change -22.71% 8.05% 30.43%
Depreciation, Depletion And Amortization $6.000K $6.000K $10.00K
YoY Change -40.0% 0.0%
Cash From Operating Activities -$2.804M -$3.046M -$2.350M
YoY Change -7.15% 29.62% 91.06%
INVESTING ACTIVITIES
Capital Expenditures -$7.000K -$2.000K $0.00
YoY Change -86.0%
Acquisitions
YoY Change
Other Investing Activities -$8.682M -$12.83M -$14.00M
YoY Change -1322.82% -8.39% -566.67%
Cash From Investing Activities -$8.689M -$12.83M -$14.00M
YoY Change -1396.87% -8.37% -566.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $30.00M $23.00M
YoY Change 30.43%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -19.00K 29.87M 21.18M
YoY Change -36.67% 41.01%
NET CHANGE
Cash From Operating Activities -2.804M -3.046M -2.350M
Cash From Investing Activities -8.689M -12.83M -14.00M
Cash From Financing Activities -19.00K 29.87M 21.18M
Net Change In Cash -11.51M 13.99M 4.830M
YoY Change 383.7% 189.67% 172.88%
FREE CASH FLOW
Cash From Operating Activities -$2.804M -$3.046M -$2.350M
Capital Expenditures -$7.000K -$2.000K $0.00
Free Cash Flow -$2.797M -$3.044M -$2.350M
YoY Change -5.82% 29.53% 91.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
132000 USD
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26439217
CY2021Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26439217
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26439217
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18746157
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18746157
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
100000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1800000 USD
dmac Stock Issued During Period Shares Exercise Of Common Stock Warrants
StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants
0
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16219000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7409000 USD
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
31878000 USD
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20098000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1624000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2028000 USD
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
7000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
46000 USD
dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
205000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
103000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
104000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
340000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
336000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
74000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
48537000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
27921000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
57000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000 USD
CY2021Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
127000 USD
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
174000 USD
CY2021Q3 us-gaap Assets
Assets
48664000 USD
CY2020Q4 us-gaap Assets
Assets
28095000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
699000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1099000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
861000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
864000 USD
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
60000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000 USD
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4000 USD
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
53000 USD
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126296000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
94925000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79255000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68909000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
47036000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26014000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48664000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28095000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2332000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2158000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6894000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5108000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1084000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1161000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3506000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3323000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3416000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3319000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10400000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8431000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
75000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
154000 USD
CY2021Q3 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
-0 USD
CY2020Q3 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
25000 USD
dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
-0 USD
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-27000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
128000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
75000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
359000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3443000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3191000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10325000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8072000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3450000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3193000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10346000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8092000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3452000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3212000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10349000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8084000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19035713
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16689074
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18863829
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14652749
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26014000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
511000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3622000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
23145000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
446000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3274000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
20318000 USD
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29867000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
303000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3450000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
47036000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7617000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7682000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
393000 USD
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2425000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
13323000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
436000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2474000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
11272000 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21190000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
508000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3193000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
29758000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10346000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8092000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1260000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1337000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-51000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
24000 USD
dmac Noncash Lease Expense
NoncashLeaseExpense
43000 USD
dmac Noncash Lease Expense
NoncashLeaseExpense
39000 USD
us-gaap Depreciation
Depreciation
18000 USD
us-gaap Depreciation
Depreciation
16000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-236000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-488000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
262000 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
13000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-400000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
538000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-48000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-458000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9448000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6169000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
47740000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
25048000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
35905000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8249000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11848000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16801000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29867000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28872000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
244000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
4000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30106000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28884000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8810000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5914000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7409000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3883000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16219000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9797000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79300000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10300000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9400000 USD
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
16200000 USD
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
31900000 USD
CY2021Q3 dmac Working Capital
WorkingCapital
46900000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of credit risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with <em style="font: inherit;">one</em> financial institution. These balances generally exceed federally insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses in such accounts and believes it is <em style="font: inherit;">not</em> exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
47000000.0 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
30000000.0 USD
CY2021Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
102000 USD
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
34000 USD
CY2021Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2000 USD
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2000 USD
CY2021Q3 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
0 USD
CY2020Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
289000 USD
CY2021Q3 us-gaap Other Receivables
OtherReceivables
0 USD
CY2020Q4 us-gaap Other Receivables
OtherReceivables
15000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
104000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
340000 USD
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
130000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
131000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
60000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
57000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
344000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
483000 USD
CY2021Q3 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
313000 USD
CY2020Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
360000 USD
CY2021Q3 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
181000 USD
CY2020Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
13000 USD
CY2021Q3 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
23000 USD
CY2020Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
8000 USD
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
861000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
864000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
49000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
41000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
17000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
46000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
63000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
60000 USD
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7653060
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.92
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30000000.0 USD
CY2021Q3 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
29900000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1260000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1337000 USD
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4600000
CY2020Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
5.00
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23000000.0 USD
CY2020Q2 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
21200000 USD
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2125000
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.00
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8500000 USD
CY2020Q1 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
7700000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7200
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
22000 USD
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2753260
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3450000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3193000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10346000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8092000 USD
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19035713
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16689074
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18863829
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14652749
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
303000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
508000 USD
CY2021Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1959100
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y6M
CY2021Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.63
CY2021Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1224883
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y8M12D

Files In Submission

Name View Source Status
0001437749-21-026175-index-headers.html Edgar Link pending
0001437749-21-026175-index.html Edgar Link pending
0001437749-21-026175.txt Edgar Link pending
0001437749-21-026175-xbrl.zip Edgar Link pending
a.jpg Edgar Link pending
dmac-20210930.xsd Edgar Link pending
dmac-20210930_cal.xml Edgar Link unprocessable
dmac-20210930_def.xml Edgar Link unprocessable
dmac-20210930_lab.xml Edgar Link unprocessable
dmac-20210930_pre.xml Edgar Link unprocessable
dmtp20210930_10q.htm Edgar Link pending
dmtp20210930_10q_htm.xml Edgar Link completed
ex_303945.htm Edgar Link pending
ex_303946.htm Edgar Link pending
ex_303947.htm Edgar Link pending
ex_303948.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending